Miscellaneous

Finally Out with the Old at PharmaNet?

Friday, November 2, 2007 12:10 PM

Some equity analysts remained on edge about PharmaNet Development Group’s recent personnel changes during its third quarter conference call on Nov. 1. But should they be?

More... »


NEJM Takes Shots at CROs

Wednesday, October 31, 2007 09:22 AM

A recent New England Journal of Medicine (NEJM) Perspective piece criticized the clinical trials industry for its reliance on contract research organizations (CROs). The piece describes the rapid growth in the CRO industry, questions the quality of research data it generates and cites various clinical trials that have shed some negative light on CRO-run studies.

More... »


Centocor Psoriasis Drug Shows Impressive Results

Monday, October 29, 2007 12:44 PM

Johnson & Johnson’s Centocor reported positive results from a phase III trial of CNTO1275 (ustekinumab) for the treatment of psoriasis. CNTO1275 is a monoclonal antibody (mAb) against the p40 subunit of interleukin 12 (IL-12) and IL-23. This randomized, double-blind, placebo-controlled study, dubbed PHOENIX 2, enrolled 1,230 subjects with chronic psoriasis.

More... »

Top Stories for the Week of Oct. 22nd 2007

Friday, October 26, 2007 12:01 PM

Top News

More... »

Recent Industry Personnel News

Wednesday, October 24, 2007 01:55 PM

Contract Research

More... »

Top Stories for the Week of Oct. 15th 2007

Friday, October 19, 2007 11:21 AM

Top News

More... »

OmniComm Inked 10 New Contracts

Friday, October 19, 2007 11:12 AM

Florida-based electronic data capture (EDC) provider OmniComm Systems inked 10 new contracts during the third quarter of 2007. The additional deals bring the company’s total contracts to 35 for the year.

More... »

CenterWatch Monthly October 2007 Issue

Wednesday, October 17, 2007 12:05 PM

Pfizer Reverses Course for Big Savings with Auctions

More... »

Gene Therapy Drug Shows Promise in MS Patients

Monday, October 15, 2007 04:45 PM

Palo Alto, Calif.-based Bayhill Therapeutics reported positive results from a phase IIb trial of BHT-3009 for the treatment of multiple sclerosis. BHT-3009 is a gene therapy drug that delivers DNA that instructs cells to produce myelin basic protein (MBP). Myelin is the phospholipid sheath that surrounds neurons and is the target of many autoimmune diseases such as MS.

More... »

Top Stories for the Week of Oct. 8th 2007

Friday, October 12, 2007 11:29 AM

Top News

More... »


CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs